Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third quarter 2020 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma's website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.


These press releases may also interest you

at 01:00
As we approach a new year, women business owners across the world will be developing strategy, setting plans and even creating resolutions for 2021. While there are about 400 million women entrepreneurs globally, according to the Global...

at 00:43
Horizons ETFs Management (Canada) Inc. ("Horizons ETFs"), the manager of the Horizons ETF Corp. (the "Company"), announced today that it does not expect that the Company will declare any dividends for the 2020 tax year. The Corporation is currently...

27 nov 2020
ZoomerMedia Limited (the "Company"), the leader in serving the interests of the 45+ "Zoomer" market in Canada, today announced its financial results for the year ended August 31, 2020. Consolidated Results For the twelve months ended August 31,...

27 nov 2020
Canadian Spirit Resources Inc. ("CSRI" or the "Corporation") announces the release of its interim financial results and Management Discussion and Analysis ("MD&A"), for the nine month period ended September 30, 2020. In addition, CSRI announces...

27 nov 2020
TSX VENTURE COMPANIES CINAPORT ACQUISITION CORP. III ("CAC.P") BULLETIN TYPE:  Suspend-Failure to Complete a Qualifying Transaction within 24 months of ListingBULLETIN DATE:  November 27, 2020,TSX Venture Tier 2 Company Further to Exchange bulletins...

27 nov 2020
iLOOKABOUT Corp. ("ILA" or "the Company") today announced that its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019, and the related Management's Discussion and Analysis...



News published on 22 october 2020 at 16:20 and distributed by: